Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAT Therapy in Sepsis
NCT04160676Completed
- Sponsor
- Tanta University
- Start
- Dec 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of hydrocortisone, ascorbic acid and thiamine in sepsis (2 arms), sponsored by Tanta University. Primary endpoint: 28th day mortality rate at 28 days. Started Dec 2019; status: completed.
02
Drugs
hydrocortisoneascorbic acidthiamine
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT04160676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04160676.